Reaads Igm ANTI-B2GPI Test Kit, Model 038-001
System,Test,Antibodies,B2 - Glycoprotein I (B2 - Gpi). 510(k) K031208, from Corgenix, Inc. (Westminster, CO). Product code MSV, class 2.
As of Nov 20, 2026, K031208 is an FDA 510(k) held by Corgenix, Inc., substantially equivalent on Jul 7, 2003 after 81 days, with no recalls tied to it in FDA's recall database.
- Review time: 81 days
- Recalls: 0
- Cited as a predicate by: 1 device
The REAADS IgM Anti-B2GPI Test Kit is an in vitro diagnostic assay for the detection and semi-quantitation of IgM anti-B2GPI antibodies in human serum or plasma as an aid for assessing the risk of thrombosis in individuals with systemic lupus erythematosus (SLE) and lupus-like disorders (antiphospholipid syndrome).
- Hemosil Acustar ANTI-B2 Glycoprotein-I; Igg, Igm, Igg Controls, Igm ControlsK091556 · Instrumentation Laboratory CO · May 21, 2010
- Aptiva APS IgA ReagentK243979 · Inova Diagnostics, Inc. · Feb 6, 2026
- Type
- Special
- Received
- Apr 17, 2003
- Review panel
- Immunology
- Regulation
- 21 CFR 866.5660
One page per 510(k), De Novo and original PMA. Recalls are those FDA's recall database ties to this number; recalls of related devices that cite another number are not shown. Refreshed weekly. Predicates are read by Arca from the text of FDA's 510(k) summary PDFs, most of them scans: a device number counts when the summary names it as a predicate or as the device it is substantially equivalent to. About 97% of those read were right on a sample we checked by hand; summaries from before 2000 often name predicates without a number, so older devices show fewer. Pivotal studies are read by a model from FDA's De Novo decision summaries and PMA SSEDs; a count or result is shown only when its numbers appear in FDA's text. openFDA device 510(k), PMA and recall files